|
WO2006031848A2
|
|
Corticosteroid topical dispersion with low content of surfactant
|
|
WO2006031665A1
|
|
Process for isolation of mycophenolic acid
|
|
WO2006026304A1
|
|
Cardioprotective formulations and uses thereof
|
|
WO2006014356A1
|
|
Process for the isolation of paclitaxel
|
|
WO2005097243A1
|
|
Small animal mask
|
|
WO2005075490A2
|
|
Synthesis of polysulfated uronic acid glycosides
|
|
WO2005027875A1
|
|
Particles
|
|
WO2005011617A2
|
|
Transmucosal dosage forms for brain-targeted steroid chemical delivery systems
|
|
CN1787809A
|
|
Oral formulations of cladribine
|
|
BRPI0408895A
|
|
Cladribine formulations for improved oral and transmucosal administration
|
|
WO2004069195A2
|
|
Methods and compositions for treating inflammatory disorders of the airways
|
|
WO03103582A2
|
|
Reduction of gelatin cross-linking
|
|
AU2003239967A1
|
|
Compound for the treatment of cns disorders
|
|
CN1612859A
|
|
Crystalline (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-heptanoic acid calcium salt (2:1)
|
|
GB9601411D0
|
|
Improvements in gelatin capsules for use as projectiles
|
